Showing posts with label Bharat Biotech. Show all posts
Showing posts with label Bharat Biotech. Show all posts

Sunday 7 March 2021

India’s Covid vaccine rollout ‘rescued the world’: Top US scientist

‘Dr Peter Hotez, Dean of the National School of Tropical Medicine at Baylor College of Medicine (BCM) in Houston during a recent webinar said that the two mRNA vaccines may not impact the world's low- and middle-income countries, but India's vaccines, made in collaboration with universities across the world such as BCM and the Oxford University, have "rescued the world" and its contributions must not be underestimated.

‘During the webinar, "Covid-19: Vaccination and Potential Return to Normalcy - If and When", Dr Hotez, an internationally-recognised physician-scientist in neglected tropical diseases and vaccine development, said that the Covid-19 vaccine rollout is "India's gift'' to the world in combating the virus.

‘India's drugs regulator gave emergency use authorisation to Covishield, produced by Pune-based Serum Institute of India after securing licence from British pharma company AstraZeneca, and Covaxin, indigenously developed jointly by Hyderabad-based Bharat Biotech and Indian Council of Medical Research scientists.’

Read here (India Today, Mar 7, 2021)

Wednesday 3 March 2021

India's Covid vaccine wins over some sceptics after promising data

‘Indian doctors and politicians on Thursday welcomed efficacy data for a state-backed coronavirus vaccine that was given emergency approval in January without the completion of a late-stage trial, making people reluctant to receive the shot.

‘Government data shows (dashboard.cowin.gov.in) that only 10% of about 13.3 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said on Wednesday.’

Read here (Reuters, Mar 4, 2021)

Friday 5 February 2021

Pfizer withdraws vaccine application in India [after failing to present needed information to experts]

‘Pfizer Inc says it has withdrawn its application for emergency use of its COVID-19 vaccine in India. The company said Friday that it participated in a meeting of experts of the drug regulator on Feb. 3. Based on the deliberation of that meeting and “our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time,” it said in a statement.

‘The company was the first to approach the Indian regulator in December for its messenger RNA vaccine that it has developed with Germany’s BioNTech. They were closely followed by applications for two other vaccines --- a version of the AstraZeneca made by Serum Institute of India and another by Indian company Bharat Biotech -- which eventually got the nod for emergency use on Jan. 3. However, India’s Health Ministry has said that Pfizer hadn’t made its presentation to experts who needed to clear the vaccine, before the regulator could green-light its use in India.’

Read here (The Independent, Feb 6, 2021)

Tuesday 19 January 2021

India to send Covaxin, Covishield to other nations as goodwill gesture

‘India has decided to export 8.1 lakh doses of Covaxin to Oman, Mongolia, Myanmar, Bahrain, Mauritius, the Philippines and the Maldives as a goodwill gesture, people in the know said. Government sources said Serum would supply a few lakh doses of Covishield to the Seychelles, Afghanistan, Bangladesh, Bhutan and Nepal.’

Read here (Economic Times, Jan 19, 2021)

Sunday 10 January 2021

Indian nasal Covid vaccine can be potential gamechanger: Experts

 Indian nasal Covid vaccine can be potential gamechanger: Experts

‘Public health experts believe that intranasal vaccines for coronavirus, administered through nose rather than muscles, can be a potential gamechanger in Indias fight against the coronavirus pandemic. The nasal vaccine is different from two intramuscular vaccines which recently got approval, as it is non-invasive, needle-free, doesn't require trained healthcare workers, eliminates needle-associated risks, suits children and adults and has scalable manufacturing.

‘Several studies have proved that the clinical efficacy of intranasal vaccine is superior to that of injectable vaccine. In India, Hyderabad-based Bharat Biotech has sought Drugs Controller General of India's (DCGI) approval to conduct clinical trials of its nasal vaccine for coronavirus.’

Read here (Khaleej Tinmes, Jan 10, 2021)

Monday 4 January 2021

India’s push to use untested vaccine rings alarm bells

‘India’s need for speed in providing a Covid-19 vaccine and attempts to push a locally-produced version through for use before a required phase 3 trial was finished has raised doubts and protests from politicians, scientists and academicians.

‘The Drugs Controller General of India (DCGI) approved the Oxford-AstraZeneca vaccine that’s being produced locally by the Serum Institute of India as Covishield. The world’s largest vaccine manufacturer based in Pune said it can readily provide 50 million vaccines to the government for immediate use and can roll out full production to start supplying the population by March.

‘The DCGI also approved a vaccine produced by Bharat Biotech Ltd along with the Indian Council for Medical Research and the National Institute of Virology named Covaxin for emergency use on a trial basis.’

Read here (Asia Times, Jan 4, 2020)

Worst ever Covid variant? Omicron

John Campbell shares his findings on Omicron.  View here (Youtube, Nov 27, 2021)